← Eichor
Condition: Epidermolysis Bullosa Junctional Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Epidermolysis Bullosa Junctional

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Phase N/A · 5 location(s) · Amryt Pharma · NCT06423573Gentamicin for Junctional Epidermolysis Bullosa
Phase 1/Phase 2 · 1 location(s) · University of Southern California · NCT03526159A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
Phase 2 · 9 location(s) · Xinnate AB · NCT06594393A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Phase 3 · 6 location(s) · Chiesi Farmaceutici S.p.A. · NCT06917690
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.